发明名称 |
Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
摘要 |
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs). |
申请公布号 |
US8999390(B2) |
申请公布日期 |
2015.04.07 |
申请号 |
US201213472219 |
申请日期 |
2012.05.15 |
申请人 |
Novartis AG |
发明人 |
Petersen Holger;Ahlheim Markus |
分类号 |
A61K9/14;A61K38/31;A61K9/16;A61K9/00;A61K9/06;A61K9/10 |
主分类号 |
A61K9/14 |
代理机构 |
|
代理人 |
Houghton Gregory;Dohmann George R. |
主权项 |
1. A sustained release pharmaceutical composition in the form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and a biocompatible polymer matrix which is a polymer blend comprising a first linear polylactide-co-glycolide polymer (PLGA) having a lactide:glycolide ratio of 85:15, a second linear PLGA having a lactide:glycolide ratio of 75:25 and a third linear PLGA having a lactide:glycolide ratio of 65:35, with each PLGA having an inherent viscosity below 0.9 dl/g in CHCl3, wherein octreotide is released from the composition at a rate which maintains plasma levels of octreotide within the therapeutic range for a period of between three and six months. |
地址 |
Basel CH |